Zhou Pi-Xiao, Zhang Ying, Zhang Quan-Bin, Zhang Guo-Qian, Yu Hui, Zhang Shu-Xu
Radiotherapy Center, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Front Oncol. 2022 Jun 17;12:898435. doi: 10.3389/fonc.2022.898435. eCollection 2022.
Functional liver imaging can identify functional liver distribution heterogeneity and integrate it into radiotherapy planning. The feasibility and clinical benefit of functional liver-sparing radiotherapy planning are currently unknown.
A comprehensive search of several primary databases was performed to identify studies that met the inclusion criteria. The primary objective of this study was to evaluate the dosimetric and clinical benefits of functional liver-sparing planning radiotherapy. Secondary objectives were to assess the ability of functional imaging to predict the risk of radiation-induced liver toxicity (RILT), and the dose-response relationship after radiotherapy.
A total of 20 publications were enrolled in descriptive tables and meta-analysis. The meta-analysis found that mean functional liver dose (f-MLD) was reduced by 1.0 Gy [95%CI: (-0.13, 2.13)], standard mean differences (SMD) of functional liver volume receiving ≥20 Gy (fV) decreased by 0.25 [95%CI: (-0.14, 0.65)] when planning was optimized to sparing functional liver (P >0.05). Seven clinical prospective studies reported functional liver-sparing planning-guided radiotherapy leads to a low incidence of RILD, and the single rate meta-analysis showed that the RILD (defined as CTP score increase ≥2) incidence was 0.04 [95%CI: (0.00, 0.11), P <0.05]. Four studies showed that functional liver imaging had a higher value to predict RILT than conventional anatomical CT. Four studies established dose-response relationships in functional liver imaging after radiotherapy.
Although functional imaging modalities and definitions are heterogeneous between studies, but incorporation into radiotherapy procedures for liver cancer patients may provide clinical benefits. Further validation in randomized clinical trials will be required in the future.
功能性肝脏成像可识别功能性肝脏分布异质性,并将其纳入放射治疗计划。目前,功能性肝脏保留放射治疗计划的可行性和临床益处尚不清楚。
对几个主要数据库进行全面检索,以识别符合纳入标准的研究。本研究的主要目的是评估功能性肝脏保留计划放射治疗的剂量学和临床益处。次要目的是评估功能成像预测放射性肝损伤(RILT)风险的能力,以及放射治疗后的剂量反应关系。
共有20篇出版物纳入描述性表格和荟萃分析。荟萃分析发现,当计划优化为保留功能性肝脏时,平均功能性肝脏剂量(f-MLD)降低了1.0 Gy [95%CI:(-0.13, 2.13)],接受≥20 Gy(fV)的功能性肝脏体积的标准平均差异(SMD)降低了0.25 [95%CI:(-0.14, 0.65)](P>0.05)。七项临床前瞻性研究报告称,功能性肝脏保留计划引导的放射治疗导致放射性肝损伤(RILD)的发生率较低,单率荟萃分析显示,RILD(定义为CTP评分增加≥2)的发生率为0.04 [95%CI:(0.00, 0.11),P<0.05]。四项研究表明,功能肝脏成像在预测RILT方面比传统解剖CT具有更高的价值。四项研究建立了放射治疗后功能肝脏成像的剂量反应关系。
尽管各研究之间的功能成像模式和定义存在异质性,但将其纳入肝癌患者的放射治疗程序可能会带来临床益处。未来需要在随机临床试验中进行进一步验证。